In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Cryptococcal meningitis (CM), caused primarily by Cryptococcus neoformans , is uniformly fatal if not treated. Treatment options are limited, especially in resource-poor geographical regions, and mortality rates remain high despite current therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Broad-spectrum antifungal activity has been observed against pathogenic yeasts and molds, including activity against resistant strains (16–18).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Potent in vitro activity of manogepix was also noticed against Cryptococcus neoformans and Cryptococcus gattii strains (Shaw et al., 2018; Pfaller et al., 2019).”
From Fungal Cell Wall: Emerging Antifungals and Drug Resistance. (2019) · cites this paper as Shaw et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 41 · Cited by 121
Research works printed but not linked: 8
- Hata K, Horii T, Miyazaki M, Watanabe NA. 2011. In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210, abstr F1-1377. Abstr 51st Intersci Conf Antimicrob Agents Chemother, Chicago, IL. American Society for Microbiology, Washington, DC.
- Zhao Y, Lee M, Lee A, Paderu P, Park S, Perlin DS. 2018. APX001 is effective against echinocandin and multi-drug resistant Candida isolates. Abstr 28th ECCMID, Madrid, Spain.
- Watanabe NA, Horii T, Miyazaki M, Hata K. 2011. In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals, abstr F1-1378. Abstr 51st Intersci Conf Antimicrob Agents Chemother, Chicago, IL. American Society for Microbiology, Washington, DC.
- Gebremariam T, Alkhazraji S, Alqarihi A, Wiederhold NP, Shaw KJ, Patterson TF, Filler SG, Ibrahim A. 2017. APX001 protects immunosuppressed mice from Rhizopus delemar infection, poster 1521. Abstr IDWeek 2017, San Diego, CA.
- Schell WA, Giamberardino C, Shaw KJ, Perfect JR. 2017. Efficacy of oral APX001 in a murine model of cryptococcal meningitis, poster 1529. Abstr IDWeek 2017, San Diego, CA.
- Mansbach RS, Shaw KJ, Hodges MR, Coleman S, Fitzsimmons ME. 2017. Absorption, distribution, and excretion of [14C]-APX001 after single-dose administration to rats and monkeys, poster 1513. Abstr IDWeek 2017, San Diego, CA.
- Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
- Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
Metadata
- Authors
- Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., Trzoss, M., Webb, P., & Perfect, J. R.
- Affiliations
- Amplyx Pharmaceuticals (United States) (US)
- Duke Medical Center (US)
- Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
- Corresponding author
- Shaw, Karen Joy
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2018-08
- Volume
- 62
- Issue
- 8
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC6105804
- OpenAlex
- W2805470919
- Cited by
- 121
- References
- 41
- Citations by year
- 2026: 12 · 2025: 10 · 2024: 17 · 2023: 17 · 2022: 12 · 2021: 18 · 2020: 14 · 2019: 17 · 2018: 4
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI073896, P01AI104533)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Keywords
- Cryptococcus, cryptococcal meningitis, antifungal agents, fungal cell wall biosynthesis, in vitro antifungal activity, in vivo antifungal activity
- MeSH terms
- Administration, Oral, Amidohydrolases, Aminopyridines, Animals, Antifungal Agents, Brain, Cryptococcus neoformans, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Combinations, Drug Synergism, Fungal Proteins, Humans, Injections, Intraperitoneal, Isoxazoles, Lung, Male, Microbial Sensitivity Tests, Organophosphates, Prodrugs, Fluconazole, Meningitis, Cryptococcal, Mice, Cryptococcus gattii
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. https://app.cochat.ai/papers/10.1128/aac.00523-18
- The paper
- Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., Trzoss, M., Webb, P., & Perfect, J. R. (2018). In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00523-18
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.